InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp

Northern Trust Corp boosted its position in InflaRx (NASDAQ:IFRX) by 1,933.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 666,845 shares of the company’s stock after purchasing an additional 634,045 shares during the period. Northern Trust Corp owned about 1.13% of InflaRx worth $1,647,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in IFRX. Raymond James Financial Inc. purchased a new position in shares of InflaRx during the 4th quarter worth approximately $1,576,000. Walleye Capital LLC purchased a new stake in shares of InflaRx in the fourth quarter valued at approximately $51,000. Commonwealth Equity Services LLC grew its holdings in InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares during the period. Geode Capital Management LLC raised its position in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in InflaRx in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IFRX shares. Oppenheimer started coverage on shares of InflaRx in a research note on Thursday, May 8th. They set an “outperform” rating and a $6.00 price target on the stock. Guggenheim boosted their price objective on shares of InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of InflaRx in a report on Friday, March 21st. Finally, Cantor Fitzgerald began coverage on shares of InflaRx in a research report on Tuesday, April 29th. They set an “overweight” rating and a $10.00 price target for the company.

InflaRx Stock Performance

InflaRx stock opened at $1.85 on Tuesday. InflaRx has a fifty-two week low of $0.82 and a fifty-two week high of $2.82. The firm has a market capitalization of $124.20 million, a price-to-earnings ratio of -1.71 and a beta of 1.57. The stock’s fifty day moving average is $1.35 and its two-hundred day moving average is $1.84.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. As a group, sell-side analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.